# A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)

> **NCT03670901** · PHASE3 · TERMINATED · sponsor: **JHL Biotech, Inc.** · enrollment: 8 (actual)

## Conditions studied

- Diffuse Large B-Cell Lymphoma

## Interventions

- **BIOLOGICAL:** JHL1101
- **BIOLOGICAL:** MabThera

## Key facts

- **NCT ID:** NCT03670901
- **Lead sponsor:** JHL Biotech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-13
- **Primary completion:** 2019-03-07
- **Final completion:** 2019-03-07
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** The development was stopped due to company's strategy consideration
- **Last updated:** 2020-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03670901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03670901, "A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03670901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*